Ophthalmology Doctors in Statesville, NC Accepting Medicare

6 Ophthalmology doctors found. Showing 1 - 6

Stanley F Sliwinski Jr., MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 208 Old Mocksville Rd, Statesville, NC 28625 Phone: 704-838-8235

Dr. Craig S Self, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 646 Hartness Rd, Statesville, NC 28677 Phone: 704-872-4108    Fax: 704-873-6517

Dr. Walter Bowlin Holland, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 646 Hartness Rd, Statesville, NC 28677 Phone: 704-872-4108    Fax: 704-873-6517

Rachel Peck Sabo, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 646 Hartness Rd, Statesville, NC 28677 Phone: 704-872-4108    Fax: 704-873-6517

Dr. Steve Malone Mckinnon, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 1835 Davie Ave, 413, Statesville, NC 28677 Phone: 704-873-1463    Fax: 704-873-1467

Dr. Brent Blair Warren, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 646 Hartness Rd, Statesville, NC 28677 Phone: 704-872-4108    Fax: 704-873-6517

News Archive

Functional MRI can be used to assess tumor viability

Pancreatic ductal adenocarcinoma (the disease commonly referred to as pancreatic cancer) carries the worst prognosis of any cancer. As current treatments offer minimal benefit, entirely new approaches are needed. Given the success of local therapies, as opposed to intravenous systemic therapies, for liver diseases (such as hepatocellular carcinoma), it is thought that similar local therapies may benefit patients with pancreatic cancer. To develop such therapies, it would be useful to devise targets that are easy to obtain and can indicate the efficacy of these new therapies in models of pancreatic cancer.

Added benefit of ipilimumab in advanced melanoma not proven for non-pretreated patients

The German Institute for Quality and Efficiency in Health Care already assessed the added benefit of ipilimumab in advanced melanoma in 2012. A considerable added benefit was found for patients who had already received previous treatment. In the new dossier compiled by the drug manufacturer, the drug was now compared with the appropriate comparator therapy dacarbazine specified by the Federal Joint Committee (G-BA) also for non-pretreated patients.

Breakthrough in cancer treatment at Mount Sinai

A 32-year-old mother of two small children, who was recently diagnosed with metastatic stomach cancer, underwent surgery using Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at The Mount Sinai Medical Center.

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the PKD Foundation today announced a collaboration to investigate novel, orally-available small molecule kinase inhibitors of the TORC1 and TORC2 complexes as a potential treatment for patients with polycystic kidney disease.

D3 FastPoint L-DFA Influenza A/ Influenza B Virus Identification Kit receives FDA clearance

Diagnostic Hybrids, a leading developer of in vitro diagnostic fluorescent staining kits and cell culture products, announces the U.S. Food and Drug Administration (FDA) (510k) clearance of its D3 FastPointTM L-DFATM Influenza A/ Influenza B Virus Identification Kit, which allows for the identification of influenza A virus and influenza B virus from a patient's specimen in under 30 minutes.

Read more Medical News

› Verified 1 days ago